Advertisement
AAPG vs EVAX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AAPG is a Buy and EVAX is a StrongBuy.
AAPG in +6.58% Uptrend, growing for three consecutive days on October 21, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where AAPG advanced for three days, in 63 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for AAPG just turned positive on October 12, 2026. Looking at past instances where AAPG's MACD turned positive, the stock continued to rise in 10 of 18 cases over the following month. The odds of a continued upward trend are 56%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 18 of 21 cases where AAPG's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.
The Momentum Indicator moved below the 0 level on October 26, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AAPG as a result. In 22 of 28 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
AAPG moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AAPG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
AAPG broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AAPG entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. AAPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.589) is normal, around the industry mean (2.974). P/E Ratio (-0.976) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (14.948) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AAPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
EVAX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EVAX turned positive on October 20, 2026. Looking at past instances where EVAX's MACD turned positive, the stock continued to rise in 42 of 46 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on EVAX as a result. In 67 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 78%.
The 10-day moving average for EVAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +43.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVAX advanced for three days, in 190 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 68 of 97 cases where EVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The 10-day RSI Indicator for EVAX moved out of overbought territory on October 21, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 21 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 42 cases where EVAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
EVAX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVAX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.877) is normal, around the industry mean (2.974). P/E Ratio (-6.080) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (3.452) is also within normal values, averaging (439.237).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. EVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
| AAPG | EVAX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 86% | 1 day ago 88% |
| Momentum ODDS (%) | 1 day ago 79% | 1 day ago 78% |
| MACD ODDS (%) | 1 day ago 56% | 1 day ago 90% |
| TrendWeek ODDS (%) | 1 day ago 87% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 90% |
| Advances ODDS (%) | 8 days ago 63% | 9 days ago 84% |
| Declines ODDS (%) | 1 day ago 82% | 1 day ago 90% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 70% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AAPG’s FA Score shows that 1 FA rating(s) are green while EVAX’s FA Score has 1 green FA rating(s).
- AAPG’s FA Score: 1 green, 4 red.
- EVAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AAPG’s TA Score shows that 2 TA indicator(s) are bullish while EVAX’s TA Score has 5 bullish TA indicator(s).
- AAPG’s TA Score: 2 bullish, 6 bearish.
- EVAX’s TA Score: 5 bullish, 5 bearish.
Price Growth
AAPG (@Biotechnology) experienced а -5.54% price change this week, while EVAX (@Biotechnology) price change was -24.94% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.36%. For the same industry, the average monthly price growth was -13.16%, and the average quarterly price growth was -14.28%.
Reported Earning Dates
AAPG is expected to report earnings on Dec 02, 2026.
EVAX is expected to report earnings on Nov 19, 2026.
Industries' Descriptions
@Biotechnology (-1.36% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
AAPG and
Correlation & Price change
A.I.dvisor tells us that AAPG and NGNE have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AAPG and NGNE's prices will move in lockstep.
| Ticker / NAME | Correlation To AAPG | 1D Price Change % | ||
|---|---|---|---|---|
| AAPG | 100% | -2.69% | ||
| NGNE - AAPG | 21% Poorly correlated | +14.66% | ||
| ACTU - AAPG | 21% Poorly correlated | -24.32% | ||
| MIST - AAPG | 21% Poorly correlated | +7.26% | ||
| EVAX - AAPG | 21% Poorly correlated | -1.30% | ||
| RCKT - AAPG | 21% Poorly correlated | +7.46% | ||
More | ||||
EVAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, EVAX has been loosely correlated with GNPX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if EVAX jumps, then GNPX could also see price increases.
| Ticker / NAME | Correlation To EVAX | 1D Price Change % | ||
|---|---|---|---|---|
| EVAX | 100% | -1.30% | ||
| GNPX - EVAX | 40% Loosely correlated | +7.73% | ||
| CYPH - EVAX | 34% Loosely correlated | +10.78% | ||
| SANA - EVAX | 33% Poorly correlated | +4.66% | ||
| NCEL - EVAX | 31% Poorly correlated | +9.16% | ||
| VYGR - EVAX | 31% Poorly correlated | -1.14% | ||
More | ||||